Tesamorelin

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH) that stimulates the production and secretion of endogenous growth hormone from the pituitary gland. The peptide consists of all 44 amino acids of human GHRH with the addition of a trans-3-hexenoic acid group at the N-terminus, which enhances its stability in serum. It was approved by the FDA in November 2010 under the brand name Egrifta as the first and only treatment specifically indicated for reducing excess visceral abdominal fat in HIV-infected patients with lipodystrophy. Clinical trials have demonstrated significant reductions in visceral adipose tissue (15-37% relative reduction), along with improvements in triglycerides, liver fat, and metabolic markers. The peptide has also shown promising effects on cognitive function in older adults and individuals with mild cognitive impairment. Tesamorelin is administered as a once-daily subcutaneous injection and is commercially available by prescription for its FDA-approved indication, though it remains under investigation for additional therapeutic applications including non-alcoholic fatty liver disease and age-related cognitive decline.

Visceral Fat Reduction

• Primary indication: FDA-approved for reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy ^[1][2]
• Significant VAT reduction: Clinical trials showed 15.2% decrease in visceral adipose tissue with tesamorelin versus 5.0% increase with placebo over 26 weeks ^[3]
• Responder rate: 69% of tesamorelin-treated patients achieved ≥8% VAT reduction compared to 33% with placebo ^[9]
• Sustained effects: Benefits maintained through 52 weeks of continued treatment, though VAT reaccumulates to near baseline levels upon discontinuation ^[9][11]

Metabolic Improvements

• Lipid profile enhancement: Significant reductions in triglycerides (mean decrease of 50 mg/dL) and improvements in cholesterol-to-HDL ratio ^[3][8]
• Liver health: 37% relative reduction in hepatic fat fraction with 35% of patients achieving hepatic fat below 5% (no longer classified as NAFLD) versus 4% with placebo ^[4]
• Liver enzyme improvement: VAT responders experienced significantly greater reductions in ALT levels (-8.9 vs 1.4 U/L) ^[7]
• Adipose tissue quality: Increases in both visceral and subcutaneous adipose tissue density independent of fat quantity changes, indicating improved fat quality ^[6]

Body Composition

• Waist circumference reduction: Significant decreases in waist circumference and trunk fat in clinical trials ^[1][2]
• Body fat reduction: 7.4% decrease in total body fat while preserving lean body mass ^[5]
• Improved body image: Statistically significant improvements in patient-reported body image parameters ^[1][11]

Cognitive Function

• Executive function enhancement: Significant improvements in executive function tests (p=0.005) in adults with mild cognitive impairment and healthy older adults ^[5]
• Verbal memory: Positive trend toward improved delayed verbal recall, particularly in MCI patients ^[5]
• IGF-1 elevation: Treatment increased IGF-1 levels by 117% within normal physiological range, potentially contributing to cognitive benefits ^[5]

Cardiovascular Risk Reduction

• ASCVD risk reduction: Modest reduction in 10-year atherosclerotic cardiovascular disease risk prediction scores, driven predominantly by cholesterol improvements ^[10]
• Inflammatory markers: Reductions in tissue plasminogen activator (tPA) antigen and increases in adiponectin, suggesting additional cardiometabolic benefits ^[8]

Glucose Homeostasis

• Preserved insulin sensitivity: No adverse effects on overall glucose tolerance or insulin-stimulated glucose uptake in HIV patients ^[1][3]
• Safety in diabetes: 12-week study in type 2 diabetic patients showed no significant changes in fasting glucose, HbA1c, or diabetes control ^[12]

Clinical Safety Profile

• FDA approval status: Approved by the FDA in November 2010 as the first treatment for HIV-associated lipodystrophy; newer formulations (EGRIFTA SV, EGRIFTA WR) approved in 2019 and 2025 ^[9][11]
• General tolerability: Well-tolerated in clinical trials with treatment-related serious adverse events occurring in less than 4% of patients ^[9]
• Long-term safety limitations: Long-term cardiovascular safety has not been established; regulatory authorities have concluded that manufacturer-submitted data are inadequate to assess long-term safety ^[11]

Common Side Effects

• Injection site reactions: Most commonly reported adverse reaction, typically mild to moderate ^[9][11]
• Musculoskeletal effects: Arthralgia, pain in extremities, and myalgia reported in clinical trials ^[11]
• Fluid retention: May include peripheral edema, arthralgia, and carpal tunnel syndrome ^[11]
• Transient glucose elevation: Temporary increase in fasting glucose observed at 2 weeks that normalized by study conclusion in some trials ^[2]

Contraindications and Warnings

• Malignancy monitoring: Pre-existing malignancy should be inactive and treatment complete prior to starting therapy; discontinue if evidence of recurrent malignancy appears ^[11]
• IGF-1 monitoring: Regular monitoring of IGF-1 levels required during therapy; consider discontinuation in patients with persistent elevations ^[11]
• Not for weight loss: Not indicated for general weight loss management as it has a weight-neutral effect on overall body weight ^[11]
• Pediatric safety unknown: Safety and effectiveness in children have not been established ^[11]

Research Gaps

• Cardiovascular outcomes: Long-term cardiovascular safety data remain limited despite modest improvements in risk prediction scores ^[10][11]
• Optimal duration: Treatment benefits are transient upon discontinuation, but optimal long-term treatment duration has not been established ^[9]
• Non-HIV populations: Limited data on safety and efficacy in populations without HIV, though studies in type 2 diabetes and cognitive impairment suggest similar safety profiles ^[5][12]
• Cancer risk: Long-term effects on cancer risk due to IGF-1 elevation require further investigation ^[11]